AI To Drive Tech Earnings


Therma Bright’s Venowave Device and the ARC Act: Advancing Vascular Health in the United States

Therma Bright Inc. (OTCQB: TBRIF) is a renowned developer and partner in the field of cutting-edge proprietary diagnostic and medical device technologies. Their commitment to addressing crucial medical and healthcare challenges is evident through their innovative solutions aimed at benefiting both consumers and medical professionals. The company’s dedication to advancing vascular health is embodied in their flagship product, the Venowave device. In a recent update, Therma Bright revealed their progress in securing unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes for Venowave, and its potential impact on patients suffering from vascular disorders. Additionally, Therma Bright is optimistic about the potential of Venowave in early prevention programs to reduce unnecessary amputations associated with peripheral artery disease (PAD) in line with the Amputation Reduction and Compassion (ARC) Act.

Venowave: Progress in the United States

In a significant development on May 31, 2023, Therma Bright engaged in productive discussions with representatives from the U.S. Department of Health and Human Services (DHHS) regarding the potential issuance of unique permanent CPT and HCPCS codes for the Venowave device. The outcome of these discussions is expected to be released by the Centers for Medicare and Medicaid Services (CMS) in August 2023. Securing these codes would be a crucial milestone, as they would enhance access to the Venowave device and empower patients to benefit from Therma Bright’s advanced vascular health solution.

Therma Bright’s CEO, Rob Fia, expressed appreciation for the collaboration with U.S. DHHS and CMS, emphasizing the company’s commitment to ensuring widespread availability of Venowave to patients in need. As part of their proactive approach, Therma Bright has been expanding its U.S.-based distribution network and commercialization efforts under the current nine (9) temporary CPT and HCPCS codes. This expansion facilitates nationwide access to Venowave for clinical groups and hospital systems, with special attention to the State of Texas, which has shown exceptional demand, particularly among Orthopedic and Podiatry groups.

Venowave and Peripheral Artery Disease (PAD)

The introduction of the Amputation Reduction and Compassion (ARC) Act by Representatives Donald Payne, Jeff Van Drew, Ruben Gallego, and Chris Smith further emphasizes the need to address peripheral artery disease (PAD). PAD affects approximately 20 million Americans, with around 200,000 patients, disproportionately people of color, experiencing avoidable amputations annually due to the disease’s complications. The ARC Act seeks to reduce PAD-related amputations by ensuring Medicare and Medicaid beneficiaries at risk receive coverage for PAD screening. Additionally, it aims to enhance education and awareness of PAD through a dedicated PAD program by the U.S. Department of Health and Human Services.

Therma Bright firmly believes that Venowave technology has the potential to contribute to early prevention programs aimed at reducing amputations associated with PAD. Venowave, designed for improving blood flow in various conditions like Deep Vein Thrombosis (DVT) or Chronic Venous Insufficiency (CVI), could be adapted to address PAD as well. By facilitating blood flow to the limbs and aiding risk factor modification, supervised exercise programs, and surveillance studies, Venowave offers promising possibilities in preventing amputations and advancing vascular health.

Therma Bright’s pursuit of cutting-edge diagnostic and medical device technologies is a testament to their commitment to improving medical and healthcare solutions. The potential issuance of unique permanent CPT and HCPCS codes for the Venowave device marks a significant step towards enhancing patient access and benefiting vascular health. As the ARC Act aims to reduce unnecessary amputations associated with PAD, Therma Bright’s Venowave technology could play a pivotal role in early prevention programs. With a focus on expanding distribution networks and commercialization efforts, Therma Bright is set to make a remarkable impact on the vibrant Southern U.S. market and beyond. Through innovative solutions like Venowave, Therma Bright continues to be at the forefront of addressing critical medical and healthcare challenges.

Therma Bright’s Core Focus

Therma Bright’s core focus centers on the development and partnership of advanced proprietary diagnostic and medical device technologies. Their vision is to provide quality, innovative solutions that effectively address some of the most pressing medical and healthcare challenges of today. As a publicly traded company, Therma Bright is listed on the TSX Venture Exchange (TSXV) under the ticker symbol “THRM,” the OTCQB market under the ticker symbol “TBRIF,” and the Frankfurt Stock Exchange (FSE) under the ticker symbol “JNX.” Further information about their products and technologies can be found on their official website,

Post Tags :

Share :

Latest News